Eccentric and irregular pigmentation prompted a biopsy in this elderly woman with a history of basal cell carcinoma and melanoma. The surprising diagnosis was a heavily pigmented squamous cell carcinoma in situ.
The FDA has approved canakinumab (Ilaris) for treatment of active systemic juvenile idiopathic arthritis) in patients aged 2 years and older. The drug is administered monthly by subcutaneous injection.
The ACR's new list of probably unnecessary procedures set this emeritus rheumatologist wondering about another procedure that might be unwarranted: MRI for low back pain or sciatica in an older patient with no red flags. What does it accomplish beyond satisfying curiosity?